Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ARTV
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Christopher Horan Chief Tech Operations Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 10,423 | $4.18 | $43.6K Sale | Form 4 ↗ |
| Nov 2, 2026 | Jennifer Bush COO, CLO, Compliance Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 8,439 | $4.18 | $35.3K Sale | Form 4 ↗ |
| Nov 2, 2026 | Subhashis Banerjee Chief Medical Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 1,110 | $4.18 | $4,641 Sale | Form 4 ↗ |
| Nov 2, 2026 | Fred Aslan Chief Executive Officer, Director | ARTV Artiva Biotherapeutics, Inc. | Sale | 62,178 | $4.18 | $260.0K Sale | Form 4 ↗ |
| Sep 8, 2026 | Fred Aslan Chief Executive Officer, Director | ARTV Artiva Biotherapeutics, Inc. | Sale | 23,429 | $10.92 | $255.8K Sale | Form 4 ↗ |
| Sep 3, 2026 | Christopher Horan Chief Tech Operations Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 10,366 | $11.16 | $115.7K Sale | Form 4 ↗ |
| Sep 3, 2026 | Jennifer Bush COO, CLO, Compliance Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 8,391 | $11.16 | $93.6K Sale | Form 4 ↗ |
| Sep 3, 2026 | Subhashis Banerjee Chief Medical Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 1,100 | $11.16 | $12.3K Sale | Form 4 ↗ |
| Sep 3, 2026 | Fred Aslan Chief Executive Officer, Director | ARTV Artiva Biotherapeutics, Inc. | Sale | 61,888 | $11.16 | $690.7K Sale | Form 4 ↗ |
| Aug 27, 2026 | Subhashis Banerjee Chief Medical Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 8,222 | $12.01 | $98.7K Sale | Form 4 ↗ |
| Aug 18, 2026 | Subhashis Banerjee Chief Medical Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 429 | $12.00 | $5,148 Sale | Form 4 ↗ |
| Jul 31, 2026 | RA Capital Healthcare Fund LP Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 24,944 | $9.93 | $247.7K Buy | Form 4 ↗ |
| Jul 29, 2026 | RA Capital Healthcare Fund LP Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 20,824 | $9.99 | $208.0K Buy | Form 4 ↗ |
| Jul 24, 2026 | RA Capital Nexus Fund III, L.P. Director | ARTV Artiva Biotherapeutics, Inc. | Buy | 41,319 | $9.99 | $412.8K Buy | Form 4 ↗ |
| Jul 23, 2026 | Peter Kolchinsky Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 59,880 | $9.96 | $596.4K Buy | Form 4 ↗ |
| Jul 22, 2026 | Peter Kolchinsky Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 84,124 | $9.93 | $835.4K Buy | Form 4 ↗ |
| Jul 21, 2026 | Peter Kolchinsky Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 120,582 | $9.55 | $1.2M Buy | Form 4 ↗ |
| Jul 17, 2026 | RA Capital Healthcare Fund LP Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 7,882 | $8.95 | $70.5K Buy | Form 4 ↗ |
| Jul 16, 2026 | RA Capital Healthcare Fund LP Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 152,472 | $8.93 | $1.4M Buy | Form 4 ↗ |
| Jul 13, 2026 | RA Capital Nexus Fund, L.P. Director | ARTV Artiva Biotherapeutics, Inc. | Buy | 6,522 | $8.94 | $58.3K Buy | Form 4/A ↗ |
| Jul 13, 2026 | Rajeev M. Shah Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 6,552 | $8.94 | $58.6K Buy | Form 4 ↗ |
| Jul 10, 2026 | Rajeev M. Shah Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 15,102 | $8.97 | $135.5K Buy | Form 4 ↗ |
| Jun 26, 2026 | Ra Capital Management, L.P. Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 1,876 | $8.98 | $16.8K Buy | Form 4 ↗ |
| Jun 25, 2026 | Ra Capital Management, L.P. Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 31,000 | $8.88 | $275.3K Buy | Form 4 ↗ |
| Jun 16, 2026 | Peter Kolchinsky Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 124,893 | $8.89 | $1.1M Buy | Form 4 ↗ |
| Jun 15, 2026 | Peter Kolchinsky Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 15,414 | $8.99 | $138.6K Buy | Form 4 ↗ |
| Jun 12, 2026 | Peter Kolchinsky Director, 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 391,019 | $8.57 | $3.4M Buy | Form 4 ↗ |
| Jun 11, 2026 | RA Capital Nexus Fund, L.P. Director | ARTV Artiva Biotherapeutics, Inc. | Buy | 548,580 | $7.91 | $4.3M Buy | Form 4 ↗ |
| Jun 10, 2026 | RA Capital Nexus Fund, L.P. Director | ARTV Artiva Biotherapeutics, Inc. | Buy | 103 | $7.00 | $721 Buy | Form 4 ↗ |
| Jun 9, 2026 | RA Capital Nexus Fund, L.P. Director | ARTV Artiva Biotherapeutics, Inc. | Buy | 479,039 | $6.91 | $3.3M Buy | Form 4 ↗ |
| May 19, 2026 | Heather Raymon SVP, Research and Development | ARTV Artiva Biotherapeutics, Inc. | Sale | 3,095 | $9.01 | $27.9K Sale | Form 4 ↗ |
| May 19, 2026 | Christopher Horan Chief Tech Operations Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 7,002 | $9.01 | $63.1K Sale | Form 4 ↗ |
| May 19, 2026 | Jennifer Bush COO, CLO, Compliance Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 8,790 | $9.01 | $79.2K Sale | Form 4 ↗ |
| May 19, 2026 | Subhashis Banerjee Chief Medical Officer | ARTV Artiva Biotherapeutics, Inc. | Sale | 7,037 | $9.01 | $63.4K Sale | Form 4 ↗ |
| May 19, 2026 | Fred Aslan Chief Executive Officer, Director | ARTV Artiva Biotherapeutics, Inc. | Sale | 27,116 | $9.01 | $244.3K Sale | Form 4 ↗ |
| May 11, 2026 | GC Corp. 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 347,222 | $11.52 | $4.0M Buy | Form 4 ↗ |
| May 11, 2026 | GC Corp. 10% owner | ARTV Artiva Biotherapeutics, Inc. | Buy | 1.09M | $11.52 | $12.5M Buy | Form 4 ↗ |
| May 11, 2026 | RA Capital Nexus Fund III, L.P. Director | ARTV Artiva Biotherapeutics, Inc. | Buy | 6.51M | $11.52 | $75.0M Buy | Form 4 ↗ |
| Dec 15, 2025 | Fred Aslan President and CEO, Director | ARTV Artiva Biotherapeutics, Inc. | Sale | 3,187 | $6.00 | $19.1K Sale | Form 4 ↗ |
| Nov 17, 2025 | Fred Aslan President and CEO, Director | ARTV Artiva Biotherapeutics, Inc. | Sale | 6,375 | $3.38 | $21.5K Sale | Form 4 ↗ |
| Oct 17, 2025 | Fred Aslan President and CEO, Director | ARTV Artiva Biotherapeutics, Inc. | Sale | 25,500 | $6.00 | $153.0K Sale | Form 4 ↗ |
| Aug 15, 2025 | Fred Aslan President and CEO, Director | ARTV Artiva Biotherapeutics, Inc. | Sale | 25,500 | $2.73 | $69.6K Sale | Form 4 ↗ |
42 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances